EGFR Exon 20 Insertions And How To Manage Patients In The UK VJOncology podcast

Artwork

Medicine Fitness VJOncology

Indhold leveret af VJOncology. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af VJOncology eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.

VJOncology Podcast « »
EGFR exon 20 insertions and how to manage patients in the UK

1y ago 37:29

Del

MP3•Episode hjem

Indhold leveret af VJOncology. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af VJOncology eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.

EGFR exon 20 insertion mutations represent 5% to 10% of EGFR mutations in patients with non-small cell lung cancer (NSCLC). Despite this form of lung cancer being hard to detect in standard genetic testing, mobocertinib and amivantamab have shown promising results in clinical trials.

In this week’s podcast, join Sanjay Popat, MBBS, FRCP, PhD, The Royal Marsden NHS Foundation Trust, London, UK, Alastair Greystoke, MBChB, MSc, PhD, MRCP, University of Newcastle & Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK, Anna Minchom, MD, MRCP, MBBCh, The Royal Marsden NHS Foundation Trust, London, UK, and Riyaz Shah, MBBS, FRCP, PhD, Kent Oncology Centre, Maidstone, UK, as will discuss the identification of EGFR exon 20 insertions and how to manage patients in the UK, based on the recent decisions made by NICE on the use of amivantamab and mobocertinib.

The post EGFR exon 20 insertions and how to manage patients in the UK appeared first on VJOncology.

… continue reading

179 episoder

#Medicine #Fitness #VJOncology

Artwork

EGFR exon 20 insertions and how to manage patients in the UK

VJOncology Podcast

14 subscribers

published 1y ago

Del

MP3•Episode hjem

Indhold leveret af VJOncology. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af VJOncology eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.

EGFR exon 20 insertion mutations represent 5% to 10% of EGFR mutations in patients with non-small cell lung cancer (NSCLC). Despite this form of lung cancer being hard to detect in standard genetic testing, mobocertinib and amivantamab have shown promising results in clinical trials.

In this week’s podcast, join Sanjay Popat, MBBS, FRCP, PhD, The Royal Marsden NHS Foundation Trust, London, UK, Alastair Greystoke, MBChB, MSc, PhD, MRCP, University of Newcastle & Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK, Anna Minchom, MD, MRCP, MBBCh, The Royal Marsden NHS Foundation Trust, London, UK, and Riyaz Shah, MBBS, FRCP, PhD, Kent Oncology Centre, Maidstone, UK, as will discuss the identification of EGFR exon 20 insertions and how to manage patients in the UK, based on the recent decisions made by NICE on the use of amivantamab and mobocertinib.

The post EGFR exon 20 insertions and how to manage patients in the UK appeared first on VJOncology.

… continue reading

179 episoder

#Medicine #Fitness #VJOncology

Kaikki jaksot

×

Velkommen til Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

Lyt til 500+ emner